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The course of fatigue and quality of life in survivors of non-Hodgkin’s lymphoma is unknown. The aims of this
study were, therefore, to assess fatigue and quality of life in patients with non-Hodgkin’s lymphoma following pri-
mary treatment, compare fatigue and quality of life in these patients with those of an age- and sex matched norma-
tive population to assess the severity of concerns and identify associations with fatigue of survivors who remained
fatigued. The population-based Eindhoven Cancer Registry was used to select all patients diagnosed with non-
Hodgkin’s lymphoma from 1999-2009. The European Organization for Research and Treatment of Cancer Quality
of Life Questionnaire and the Fatigue Assessment Scale were completed once by 824 survivors of non-Hodgkin’s
lymphoma (80% response rate); 434 survivors completed these questionnaires again 1 year later. Survivors of non-
Hodgkin’s lymphoma reported more clinically relevant fatigue up till 10 years post-diagnosis compared to a norma-
tive population (P<0.001). Mean fatigue scores remained fairly stable over time (T1: x–=28, SD=26; T2: x–=30, SD=27,
P=0.14): 22-28% of survivors reported deterioration, 19-23% reported improvement and 44-54% reported constant
fatigue. Survivors who reported constant fatigue were more often diagnosed with stage IV disease and had more
comorbid diseases. They were additionally more often female and divorced. Having comorbidities and being with-
out a partner were also associated with constant fatigue in the normative population. In conclusion, six out of every
ten responding non-Hodgkin’s lymphoma survivors reported a high level of fatigue up till 10 years after diagnosis.
Mean fatigue scores remained stable over time and survivors reporting constant fatigue more often had stage IV dis-
ease at diagnosis and comorbidities.
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ABSTRACT
Introduction
As a result of new therapies, the survival of patients with
non-Hodgkin’s lymphoma (NHL) has improved considerably.
Although the statistics vary, depending on the type of NHL,
stage of disease at diagnosis, treatment, and age of the
patient, the overall 5-year relative survival rate for all types of
NHL (2001-2007) is 50-62%.1 A person diagnosed with can-
cer is defined as a survivor from the moment of diagnosis
through the rest of his or her life.2 The number of NHL sur-
vivors in the USA increased from approximately 347,000 in
2001 to approximately 454,000 in 2008.1 In the Netherlands
there were approximately 19,600 NHL survivors at the end of
2008.3,4
As many cancer survivors live longer, they are at risk of
adverse physical and psychosocial long-term effects, second-
ary tumors, and recurrence as a result of their cancer and/or
of their medical treatments.5-7 These long-term effects, such
as fatigue, depression, marital disruption, and problems with
infertility, can have a negative influence on survivors’ health-
related quality of life (HRQOL).8-12
In the last decades, more attention is being paid to HRQOL
after cancer diagnosis. Some studies have investigated
HRQOL and fatigue in NHL survivors,13-21 but almost all used
a cross-sectional approach (only one measurement at a
defined time).13,17-21 However, the longitudinal course of
fatigue and HRQOL in patients with NHL and their return to
normal life remains largely unknown. The aims of the present
study were, therefore, to: (i) assess fatigue and HRQOL twice
following primary treatment, (ii) compare fatigue and
HRQOL with an age- and sex matched normative population
to assess the severity of the concerns, and (iii) identify asso-
ciations with fatigue in survivors who remained fatigued.
Design and Methods
Setting and population
This study is part of a dynamic, longitudinal, population-based sur-
vey among NHL survivors registered with the Eindhoven Cancer
Registry (ECR) of the Comprehensive Cancer Centre South (CCCS).
The ECR records data on all patients who are newly diagnosed
with cancer in the southern part of the Netherlands, an area with
2.3 million inhabitants, 18 hospital locations and two large radio-
therapy institutes. The ECR was used to select all patients who
were diagnosed with NHL between January 1st, 1999 and July 1st,
2009. We included all patients with indolent (including chronic
lymphocytic leukemia) and aggressive B-cell NHL as defined by
the International Classification of Diseases for Oncology-3 (ICD-
O-3) codes.22
Participants aged ≥85 years at time of the first measurement
were excluded, because they would likely have had difficulty in
completing self-administered questionnaires without assistance.
To exclude patients who had died, our database was linked on
every measurement with the database of the Central Bureau for
Genealogy, which collects data on all deaths of Dutch citizens
through the civil municipal registries. Ethical approval for the
study was obtained from a local, certified Medical Ethics
Committee.
Study measures
We used the Dutch validated version of the European
Organization for Research and Treatment of Cancer Quality of
Life Questionnaire Core-30 (EORTC QLQ-C30) to assess HRQOL
and fatigue. Answer categories range from one (not at all) to four
(very much). After linear transformation, all scales and single item
measures range in score from 0 to 100. A higher score on function
scales and global health and quality of life scales implies a better
HRQOL, whereas for symptoms a higher score refers to more
symptoms.23
Fatigue was also assessed with the Fatigue Assessment Scale
(FAS), a questionnaire consisting of ten items: five questions
exploring physical fatigue and five questions exploring mental
fatigue. The response scale is a 5-point scale (1 never to 5 always)
and scores can range from 10 to 50. A score >21 indicates substan-
tial fatigue. The psychometric properties are good.24,25
Comorbidity at the time of the survey was categorized accord-
ing to the adapted Self-administered Comorbidity Questionnaire
(SCQ).26 Survivors’ marital status and educational level were also
assessed in the questionnaire. Clinical information was available
from the ECR which routinely collects data on tumor characteris-
tics, including date of diagnosis, tumor grade, histology, Ann
Arbor stage,27 primary treatment, and patients’ background char-
acteristics, including gender and date of birth. 
Data collection
Data were collected within PROFILES (Patient Reported
Outcomes Following Initial treatment and Long term Evaluation
of Survivorship). PROFILES is a registry for the study of the phys-
ical and psychosocial impact of cancer and its treatment from a
dynamic, growing population-based cohort of both short and
long-term cancer survivors. PROFILES contains a large web-based
component and is linked directly to clinical data from the ECR.
Details of the data collection method have been described previ-
ously.28
From May until November 2009, patients diagnosed between 6
months and 10 years previously received the baseline question-
naire (T1). A year later, patients who were willing to participate
again received a 1-year follow-up questionnaire (T2). 
EORTC QLQ-C30, SCQ, marital status and educational level
data were also collected from an age-and sex-matched normative
population29 for comparison with the NHL survivors.
Statistical analyses
All statistical analyses were performed using SAS (version 9.1
for Windows; SAS Institute Inc., Cary, NC, USA). P values <0.05
were considered statistically significant. Clinically relevant differ-
ences were determined using evidence-based guidelines for the
interpretation of EORTC QLQ-C30 scores between groups30 and
changes in scores31 and Norman’s ‘rule of thumb’ was used for the
FAS whereby a ± 0.5 SD difference indicates a threshold of dis-
criminating change in HRQOL scores.32
Differences in socio-demographic and clinical characteristics
between respondents and non-respondents or patients with
unverifiable addresses and patients who completed one or two
questionnaires were compared with a chi-square or t-tests, where
appropriate. The mean EORTC QLQ-C30 scores among the NHL
survivors were compared with those from an age- and sex-
matched Dutch normative population using independent sample
t-tests. Paired sample t-tests were performed to compare the mean
EORTC QLQ-C30 (both NHL survivors and the normative popu-
lation) and FAS (only NHL survivors) Fatigue scale scores on T1
and T2.
Multivariate logistic regression analyses were carried out to
investigate the independent association between the socio-demo-
graphic and clinical variables and constant fatigue (versus not con-
stant fatigue). The “constant fatigue group” was defined by sur-
vivors/respondents of the normative population who had a
Fatigue score >22 on both T1 and T2 for the EORTC QLQ-C30
(i.e. at least a small, clinically relevant higher score than that of the
normative population30) versus the group who did not have a
fatigue score >22 on both T1 and T2. With respect to the FAS, the
“constant fatigue group” was defined by survivors who had a
Fatigue score >21 on both T1 and T2 (i.e. indication of substantial
fatigue25) versus the group who did not have a fatigue score >21 on
both T1 and T2.
Results
Characteristics of the patients and normative population
Eight hundred and twenty-four NHL survivors complet-
ed the first questionnaire (80% response rate).
Subsequently, 434 (53%) survivors completed this ques-
tionnaire again 1 year later, which represents 36% of the
total group of NHL survivors. Of the 1731 respondents of
the normative population who completed the EORTC
QLQ-C30, 602 could be age- and sex-matched with the
NHL survivors. Of those 602, 515 (86%) respondents
completed the questionnaire again 1 year later.
Survivors with unverifiable addresses were more often
female and younger compared to respondents, and non-
respondents were more often diagnosed with indolent
NHL and less often diagnosed with stage I disease (Table
1). 
The mean age at completion of the baseline survey was
63.5 years with a mean time since diagnosis of 4.2 years.
Chemotherapy was the most frequent primary treatment
(42%; Table 1). Two-thirds of survivors reported one or
more comorbid conditions, the most common being
arthritis, back pain and hypertension (Table 2). In the age-
and sex-matched normative population, the mean age at
completion of the baseline survey was 63.5 years. Almost
two thirds (65%) of respondents reported one or more
comorbid conditions, the most common again being
hypertension, back pain and arthritis (Table 2). 
A comparison between survivors who completed one or
both questionnaires indicated that those who completed
both questionnaires had a significantly longer mean time
since diagnosis at time of first enrollment (4.2 versus 5.1
years, P<0.001) and more often had a high educational
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level (19% versus 25%, P=0.013). No differences were
observed between these groups for EORTC QLQ-C30
Fatigue (x– =28.6 versus x– =28.3, P=0.88) or FAS Fatigue
scores (x– =21.9 versus x– =21.4, P=0.33).
Health-related quality of life and fatigue among 
survivors of non-Hodgkin’s lymphoma and 
the normative population
Compared to an age- and sex-matched normative popu-
lation, responding NHL survivors had, on average, worse
scores for the EORTC QLQ-C30 Physical, Role, Cognitive
and Social Functioning domains. NHL survivors also
reported more Fatigue, Dyspnea, Sleeping Problems,
Appetite Loss, Diarrhea and Financial Problems (all
P≤0.001 and clinically relevant; Figure 1A and 1B). Scores
between survivors of indolent and aggressive NHL were
not significantly different. No clinically significant differ-
ences were found in EORTC QLQ-C30 mean fatigue
scores depending on years since diagnosis (Figure 2). 
Thirty-nine percent (n=321) of the NHL survivors did
not have clinically relevant worse scores, i.e. they had a ≤5
point difference, for the EORTC QLQ-C30 Fatigue scale
than the normative population. The other 61% did have
clinically relevant worse scores for Fatigue, with the differ-
ence being small (>5 to 13 point difference) in 17%
(n=140) of survivors; medium (>13 to 19 point difference)
in 15% (n=124) and large (>13 point difference) in 29%
(n=239).
Fatigue over time
The 1-year follow-up questionnaire was completed by
434 NHL survivors and 514 respondents of the normative
population. With respect to FAS Fatigue (NHL survivors
only), mean scores remained significantly stable over time
(T1: x– =21; T2: x– =22, Table 3). However, 22% reported
deteriorated fatigue scores with a mean difference of 6.4
and 19% reported improved scores with a mean differ-
ence of 5.9. With respect to the EORTC QLQ-C30 Fatigue,
mean scores also remained significantly stable over time
(T1: x– =28; T2: x– =29, Table 3), 32% reported deteriorated
scores with a mean difference of 21 points, and 31%
showed improved scores with a mean difference of 19
points. Similar mean scores and percentages of deteriora-
tion and improvement were observed when focusing on
diffuse large B-cell lymphoma or follicular lymphoma only
(Table 3). Mean scores of the normative population
changed slightly over time (T1: x– =17; T2: x– =18, P<0.04;
Table 2) with 31% reporting deteriorated and 24% report-
Fatigue in NHL survivors
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Table 1. Socio-demographic and clinical characteristics of questionnaire
respondents, non-respondents, and patients with unverifiable addresses.
N(%)
Respondents Non- Patients with P value
respondents unverifiable
addresses
N=824 N=212 N=184
Sex 0.021
Male 509 (62) 128 (61) 94 (51)
Female 315 (38) 84 (39) 90 (49)
Age at time 63.5 (12.4) 62.4 (14.0) 60.3 (14.8) 0.021
of survey: mean (SD)
<55 years 189 (23) 58 (27) 62 (34)
55-69 years 336 (41) 75 (35) 59 (32)
70+ years 299 (36) 79 (37) 63 (34)
Years since diagnosis: 4.2 (2.7) 4.3 (2.9) 5.1 (2.9) 0.12
mean (SD) 
0-1 years 168 (20) 64 (30) 32 (17)
2-4 years 316 (38) 70 (33) 65 (35)
5-7 years 210 (25) 44 (21) 50 (27)
8-10 years 130 (16) 34 (16) 37 (20)
Stage at diagnosis 0.012
I 202 (25) 41 (19) 48 (26)
II 127 (15) 33 (16) 20 (11)
III 116 (14) 23 (11) 19 (10)
IV 202 (25) 44 (21) 51 (28)
Unknown# 177 (21) 71 (33) 46 (25)
Grade 0.042
Indolent 443 (54) 134 (63) 106 (56)
Aggressive 381 (46) 78 (37) 78 (44)
Primary treatment 0.05
Radiotherapy 75 (9) 21 (10) 21 (11)
Chemotherapy 345 (42) 65 (31) 63 (34)
RT+CH* 99 (12) 29 (14) 21 (11)
Active surveillance+ 224 (27) 76 (36) 63 (34)
CH±RT+Transplant* 11 (1) 6 (3) 0 (0)
S±RT±CH* 70 (9) 14 (7) 16 (9)
1P value reflects differences between respondents and patients with unverifiable addresses. 2P
value reflects differences between respondents and non-respondents. #Tumor stage could not be
determined in some subtypes of indolent non-Hodgkin’s lymphoma. *RT: radiotherapy, CH:
chemotherapy, Transplant: autologous stem cell or bone marrow transplantation, S: surgery ±:
with or without. +Patients under active surveillance but not receiving therapy.
Table 2. Socio-demographic characteristics of NHL survivors (n=824),
and respondents of an age- and sex-matched normative population
(n=602).
                                                               N. (%)                     N. (%)
                                                         NHL survivors       Norm population
                                                               N=824                    N=602
Sex                                                                                                                 
Male                                                               509 (62)                      400 (66)
Female                                                          315 (38)                      202 (34)
Age at time of survey: mean (SD)           63.5 (12.4)                 63.5 (13.2)
<55 years                                                      189 (23)                      144 (24)
55-69 years                                                    336 (41)                      242 (40)
70+ years                                                      299 (36)                      216 (36)
Self-reported comorbidity                                                                      
No comorbid condition                             215 (26)                      214 (36)
1 comorbid condition                                 245 (30)                      166 (28)
2 comorbid conditions                              155 (19)                      112 (19)
> 2 comorbid conditions                          148 (18)                      108 (18)
Most frequent comorbid conditions                                                     
Arthritis                                                         183 (22)                      125 (21)
Back pain                                                       177 (21)                      178 (30)
Hypertension                                               164 (20)                      173 (29)
Marital status                                                                                              
Partner                                                          646 (78)                      460 (76)
Alone                                                                41 (5)                        142 (24)
Divorced                                                          41 (5)                       Unknown
Widowed                                                        80 (10)                      Unknown
Education level$                                                                                          
Low                                                                139 (17)                        36 (6)
Medium                                                         485 (59)                      338 (56)
High                                                               179 (22)                      224 (37)
$Education levels were low = none/primary school; medium = lower general second-
ary education/vocational training; or high = pre-university education/ high level voca-
tional training/university.
ing improved EORTC QLQ-C30 Fatigue scores.
Of NHL survivors, 54% reported constant EORTC
QLQ-C30 Fatigue, i.e. had a Fatigue score above 22 for
both T1 and T2. Of respondents of the normative popula-
tion, 30% reported constant EORTC QLQ-C30 Fatigue.
With respect to FAS Fatigue, 40% of NHL survivors
reported constant fatigue i.e. had a Fatigue score above 21
on both T1 and T2.
Associations with fatigue
Multivariate logistic regression analyses showed that
NHL survivors who reported constant fatigue (on both
EORTC QLQ-C30 and FAS) were more often diagnosed
with stage IV disease and more often reported comorbid
diseases. They were additionally more often female and
divorced (Table 4). Survivors who remained fatigued
(however only on FAS fatigue) were also more often diag-
nosed longer ago, were under active surveillance and had
a lower educational level.
With respect to survivors of diffuse large B-cell and follic-
ular lymphoma, survivors who reported constant fatigue
(on both the EORTC QLQ-C30 and FAS) reported comor-
bid diseases more often. Survivors of follicular lymphoma
who reported constant fatigue were also more often
females; however, this was only found on the FAS (Table 4).
Respondents of the normative population who reported
constant fatigue also reported comorbid diseases more
often and more often had no partner (Table 4).  
Discussion
The majority of NHL survivors showed a constant, high
level of fatigue in this population-based study up to 10
years after diagnosis. Six out of 10 survivors reported clin-
ically relevant worse fatigue scores compared to the nor-
mative population. HRQOL was also worse to a clinically
relevant degree among survivors. Mean fatigue scores
remained significantly stable over time; 22-28% reported
clinically relevant deterioration, whereas 19-23% reported
clinically relevant improvement; 44-54% reported con-
stant fatigue. No clinically significant differences in
EORTC QLQ-C30 mean fatigue scores were observed in
relation to years since diagnosis. 
Changes over time in NHL survivors have so far been
investigated in three small studies, only including short-
term survivors for a maximum of 18 months after primary
treatment. One prospective study found no clinically sig-
nificant change in mean EORTC QLQ-C30 Fatigue
scores16. One Dutch study and another Norwegian study
showed mean deteriorations in EORTC QLQ-C30 Fatigue
scores of 14 and 10 points when comparing start of treat-
ment scores with those at 18 months and 1 year of follow
up, respectively.14,15 A limitation of these studies is that
they all focused on mean differences. Mean scores do not
reflect individual changes. Given the large standard devia-
tions, there must be high degrees of variations within
these groups. A better way is, therefore, to make a distinc-
tion between patients who improved and patients who
deteriorated. 
The present study showed that survivors with stage IV
disease and comorbid conditions more often reported con-
stant fatigue. Females and divorced survivors were also
more likely to remain fatigued. In the normative popula-
tion, we also observed a relation between comorbidity
and having a partner and fatigue. This relation is not,
therefore, specific to NHL survivors but is probably appli-
cable to people in general. Type of NHL (aggressive or
S. Oerlemans et al.
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Figure 1. (A) Differences in EORTC QLQ-C30 mean functioning and global quality of life scores between survivors of aggressive NHL (n=379),
indolent NHL survivors (n=445) and an age- and sex-matched normative population (n=602) *P<0.001**P<0.001 and small clinically impor-
tant differences.30 A higher score implies a better HRQOL. (B) Differences in EORTC QLQ-C30 mean symptom scores between survivors of
aggressive NHL (n=379), indolent NHL (n=445) and an age- and sex-matched normative population (n=602)*P<0.001; **P<0.001 and small
clinically important differences;30 ***P<0.001 and medium clinically important differences.30 A higher score indicates to more symptoms.
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indolent), treatment, and survival time since diagnosis
were not associated, or only associated with one measure
of fatigue in NHL survivors. The ECR collects data on pri-
mary treatment only. More detailed treatment informa-
tion, longitudinally assessed, will enable us to study the
relation between initial treatment and HRQOL and
fatigue in more detail. Furthermore, detailed information
about disease progression could also contribute to unrav-
eling the course of HRQOL and fatigue and will help
health care providers to give their patients better informa-
tion about their expected HRQOL. As our HRQOL study
is embedded in PHAROS (Population based
HAematological Registry for Observational Studies) in
which more detailed disease and treatment information is
collected, as well as long-term side effects, we will be able
to determine this relation better in the near future.  
NHL survivors reported worse HRQOL compared to
that of an age- and sex-matched normative population.
Clinically relevant worse scores for survivors were
observed for fatigue, appetite loss, diarrhea, dyspnea and
all function scales including financial problems. One
prospective and three cross-sectional studies also observed
clinically worse scores for HRQOL domains for NHL sur-
vivors compared with those of a normative popula-
tion.13,15,17,20
Numerous patients in our study showed large improve-
ments (19-23%) or deteriorations (22-28%) within 1 year,
which both indicate a clinically relevant change.31
However, it is too soon to determine whether this can be
defined as an actual change, due to regression to the mean.
A longer follow-up time is needed to identify whether
these differences can be considered as real changes or fluc-
tuations over time.   
Significant differences were not observed between
patients with indolent or aggressive NHL, recapitulating
findings in an American cross-sectional study,33 nor
between short- or long-term survivors, confirming results
of a cross-sectional study among 761 NHL survivors.20
This suggests that there is no improvement in time, which
is also shown by our 1-year follow-up results.  
Prevalence rates for cancer-related fatigue vary widely.
Percentages between 32% and 60% have been reported34-
36 and in a recently published study an overall prevalence
of 48% was found.37 The observed percentage of 61% in
this study is somewhat higher. In our study, 29% of sur-
vivors reported large, clinically important fatigue, whereas
15% reported medium clinically important fatigue, mak-
ing a total of 44%. Adding the survivors with small, clini-
cally important fatigue produced the observed total of
61% of patients with cancer-related fatigue. Besides differ-
ences between types of cancer, the use of different cut-off
scores and fatigue assessment instruments contribute to
the differences in reported prevalences.38-40
The underlying mechanisms that cause constant cancer-
Fatigue in NHL survivors
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Table 3. Mean fatigue scores (SD) at baseline (T1) and follow-up (T2) among NHL survivors and respondents of the normative population who
completed two questionnaires (NHL survivors; n=434; normative population, n=515), and percentages of patients/respondents who deteriorat-
ed/improved between these time points (mean difference and SD). 
Baseline (T1) Follow-up (T2) Deteriorated Improved
Mean (SD) Mean (SD) P % Mean difference (SD) % Mean difference (SD)
FAS Fatigue 
NHL survivors in total (n=434) 21 (7.6) 22 (7.6) 0.18 22% 6.4 (2.7) 19% 5.9 (2.3)
FAS Fatigue 
Large B-cell NHL survivors (n=132) 22 (7.2) 22 (7.6) 0.93 19% 7.0 (3.6) 22% 5.8 (1.6)
FAS Fatigue 
Follicular NHL survivors (n=82) 22 (8.2) 22 (7.6) 0.50 22% 6.4 (2.7) 17% 6.7 (4.3)
EORTC Fatigue
NHL survivors in total (n=434) 28 (26) 29 (26) 0.42 32% 21 (13) 31% 19 (11)
EORTC Fatigue
Large B-cell NHL survivors (n=132) 29 (26) 28 (25) 0.81 33% 21 (13) 13% 22 (13)
EORTC Fatigue
Follicular NHL survivors (n=82) 28 (25) 27 (24) 0.79 32% 19 (9.3) 35% 18 (8.1)
EORTC Fatigue
Normative population 17 (19) 18 (21) 0.04 31% 20 (12) 24% 19 (10)
Deterioration and improvement determined using the guideline of at least a clinically small difference with respect to the EORTC30(deterioration >5 point difference; improvement
>4 point difference) and Norman’s rule of thumb for the FAS32 (half SD, i.e.3.8 for both deterioration and improvement). 
Figure 2. Differences between EORTC QLQ-C30 fatigue scores of all
NHL survivors (n=824) according to years survived since diagnosis
and an age- and sex-matched normative population (N=602). All
P<0.001 and small or medium clinically important differences.30 A
higher score indicates more fatigue.
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Years since diagnosis
related fatigue are not yet clear.41 Many factors are associ-
ated with the development of fatigue, such as type of
treatment, the disease itself, medication-related adverse
events, biological modifiers (such as interferon), depres-
sion, physical inactivity, anxiety, pain and sleep distur-
bances.42-46 Although the cause of fatigue is not completely
clear, results of a recently published review47 show that
patients with fatigue may benefit from pharmacological
and/or non-pharmacological treatments, such as cogni-
tive-behavioral interventions and exercise.48 Further
research is necessary to determine whether an early inter-
vention for fatigue can reduce this long-term complication
and whether patients can benefit from late intervention.
The present study had the following limitations:
although information was available concerning socio-
demographic and clinical characteristics of the non-
respondents and patients with unverifiable addresses, it
remains unknown whether non-respondents declined to
participate in the study because of poor health or the
absence of symptoms. Comparing patients who complet-
ed one questionnaire with patients who completed two
questionnaires only indicated differences in mean time
since diagnosis and educational level. This perhaps result-
ed in a small selection bias. In addition, there is always an
uncertainty with the reproducibility of self-reported ques-
tionnaires. Some of the changes might be ascribed to that
arbitrariness. 
The strengths of our study are the population-based
sampling frame instead of a hospital-based sampling
frame. Furthermore, the large range in elapsed time since
diagnosis facilitates extrapolation of the results to a broad
range of NHL survivors in the population. In addition, the
longitudinal design provides important information about
development over time. 
In conclusion, six out of every ten NHL survivors report-
ed a high level of fatigue up until 10 years after diagnosis.
HRQOL and fatigue scores of survivors were clinically rel-
evant and worse than those of an age- and sex-matched
normative population. Fatigue mean scores remained sig-
nificantly stable over time and 44-54% of survivors report-
ed constant fatigue. Survivors with stage IV disease,
comorbid conditions as well as females and divorced sur-
vivors were more likely to remain fatigued. Having
comorbidities and being without a partner were also asso-
ciated with continuous  fatigue in the normative popula-
tion. As research on the underlying determinants of
S. Oerlemans et al.
484 haematologica | 2013; 98(3)
Table 4. Odds ratios with confidence intervals (CI) of the multivariate logistic regression model evaluating independent variables for EORTC QLQ-
C30 and FAS Fatigue scores for patients (n=434) and respondents of the normative population (n=515) who completed two questionnaires and
remained fatigued.
Independent variable FAS Fatigue EORTC Fatigue
All NHL Large Follicular All Large Follicular Normative
survivors B-cell NHL NHL NHL survivors     B-cell NHL NHL population      
Odds ratio (CI) Odds ratio (CI) Odds ratio (CI) Odds ratio (CI) Odds ratio (CI) Odds ratio (CI) Odds ratio (CI)
Age (time of questionnaire) ns ns ns ns ns ns ns
Sex (women) 1.6 (1.0-2.5)* ns 3.4 (1.3-8.7)* 1.6 (1.0-2.5)* ns ns ns
Time since diagnosis 1.1 (1.0-1.2)* ns ns ns ns ns NA
Tumor stage NA
Stage 1 (reference) - - - - - - NA
Stage 2 ns ns ns ns ns ns NA
Stage 3 ns ns ns ns ns ns NA
Stage 4 2.3 (1.0-5.2)* ns ns 2.7 (1.2-5.8)* ns ns NA
Aggressive tumor grade ns NA NA ns NA NA NA
Radiotherapy (yes) ns ns ns ns ns ns NA
Chemotherapy (yes) ns ns ns ns ns ns NA
Active surveillance (yes) 2.9 (1.0-8.1)* ns ns ns ns ns NA
Comorbidities
None (reference) - - - - - - -
1 2.7 (1.4-5.1)* ns ns 1.8 (1.0-3.2)* 2.9 (1.1-8.0)* ns 2.0 (1.1-3.7)*
2 3.9 (1.9-8.3)* ns 10.2 (2.2-47.1)* ns ns 6.5 (1.3-33.9)* 4.3 (2.2-8.2)*
>2 7.2 (3.3-15.7)* 6.3 (1.7-23.8)* 26.8 (5.3-135.7)* 4.7 (2.2-10.1)* 7.2 (1.9-27.6)* 13.9 (2.3-82.9)* 16.1 (7.9-32.9)*
Marital status
Partner (reference) - - - - - NA
Divorced 6.0 (1.9-18.7)* ns ns 3.5 (1.1-11.1)* ns ns NA
Widowed ns ns ns ns ns ns NA
Alone ns ns ns ns ns ns NA
Marital status
Partner (reference) - - - - - - -
No partner ns ns ns ns ns ns 2.7 (1.6-4.6)*
Education level
Low 2.2 (1.1-4.5)* ns ns ns ns ns ns
Middle (reference) - - - - - - -
High ns ns ns ns ns ns ns
Note. *P<0.05; ns: not significant, NA: not applicable.
fatigue proceeds, health care providers should continue to
screen patients on their level of fatigue and inform them
about possible rehabilitation programs.
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